- Home
- RDIB vs BIOA Comparison
RDIB vs BIOA Comparison
Compare RDIB & BIOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDIB
- BIOA
- Stock Information
- Founded
- RDIB 1937
- BIOA 2015
- Country
- RDIB United States
- BIOA United States
- Employees
- RDIB N/A
- BIOA N/A
- Industry
- RDIB Movies/Entertainment
- BIOA Biotechnology: Pharmaceutical Preparations
- Sector
- RDIB Consumer Discretionary
- BIOA Health Care
- Exchange
- RDIB Nasdaq
- BIOA Nasdaq
- Market Cap
- RDIB 140.2M
- BIOA 167.8M
- IPO Year
- RDIB N/A
- BIOA 2024
- Fundamental
- Price
- RDIB $9.20
- BIOA $4.12
- Analyst Decision
- RDIB
- BIOA Hold
- Analyst Count
- RDIB 0
- BIOA 4
- Target Price
- RDIB N/A
- BIOA $5.67
- AVG Volume (30 Days)
- RDIB 8.9K
- BIOA 124.4K
- Earning Date
- RDIB 08-13-2025
- BIOA 08-15-2025
- Dividend Yield
- RDIB N/A
- BIOA N/A
- EPS Growth
- RDIB N/A
- BIOA N/A
- EPS
- RDIB N/A
- BIOA N/A
- Revenue
- RDIB $205,644,000.00
- BIOA $1,451,000.00
- Revenue This Year
- RDIB $7.47
- BIOA N/A
- Revenue Next Year
- RDIB $13.22
- BIOA N/A
- P/E Ratio
- RDIB N/A
- BIOA N/A
- Revenue Growth
- RDIB N/A
- BIOA N/A
- 52 Week Low
- RDIB $5.78
- BIOA $2.88
- 52 Week High
- RDIB $15.50
- BIOA $26.62
- Technical
- Relative Strength Index (RSI)
- RDIB 43.37
- BIOA N/A
- Support Level
- RDIB $10.08
- BIOA N/A
- Resistance Level
- RDIB $11.19
- BIOA N/A
- Average True Range (ATR)
- RDIB 0.78
- BIOA 0.00
- MACD
- RDIB -0.02
- BIOA 0.00
- Stochastic Oscillator
- RDIB 20.08
- BIOA 0.00
About RDIB Reading International Inc Class B
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial, and live theater assets.
About BIOA BioAge Labs Inc. Common Stock
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others.